Pricing of Offering, FDA Approvals, Launches, and Technical Updates - Analyst Notes on Tenet, Lannett, Wright Medical Group, Anika Therapeutics and Accuray

NEW YORK, June 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp. (NYSE: THC), Lannett Company, Inc. (NYSE: LCI), Wright Medical Group Inc. (NASDAQ: WMGI), Anika Therapeutics Inc. (NASDAQ: ANIK) and Accuray Incorporated (NASDAQ: ARAY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3879-100free.

--
Tenet Healthcare Corp. Analyst Notes
On June 11, 2014, Tenet Healthcare Corp. (Tenet) announced the pricing of the previously announced private offering of senior notes maturing in 2019 (the "notes"). According to the Company, the notes are offered as reopening of Tenet's 5.00% Senior Notes due 2019 issued on March 10, 2014. Tenet stated that a total of $500 million aggregate principal amount of notes will be issued at a premium of 101.50%, and will bear interest at a rate of 5.00% per annum. According to the Company, proceeds from the offering will be used to redeem the Company's 9.25% Senior Notes due 2015 and to pay related transaction fees and expenses. The full analyst notes on Tenet are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/THC/report.pdf

--
Lannett Company, Inc. Analyst Notes
On June 16, 2014, Lannett Company, Inc. (Lannett) announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for Codeine Sulfate Tablets USP. According to the Company, it expects to commence shipping of the approved product within the coming months. Lannett's President and CEO, Arthur P. Bedrosian, stated, "Codeine Sulfate Tablets USP 15 mg, 30 mg and 60 mg is our second product approved by the FDA thus far in 2014. We currently have a number of product applications pending at the FDA and are hopeful to receive additional product approvals in the coming months. In addition, we continue to develop our pipeline, which includes 55 products in various stages of development." The full analyst notes on Lannett are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/LCI/report.pdf

--
Wright Medical Group Inc. Analyst Notes
On June 16, 2014, Wright Medical Group Inc. (Wright Medical Group) announced the full U.S. commercial launch of the Company's INFINITY® Total Ankle Replacement (TAR) System, which is now available in the U.S. through Wright Medical Group's foot and ankle sales force and will also be made available in select countries outside the U.S. through the Company's direct sales organization on a limited basis. Wright Medical Group President and CEO, Robert Palmisano, stated, "With the addition of INFINITY to our existing ankle portfolio, which includes the widely acclaimed INBONE total ankle system, Wright is first to offer best-in-class total ankle replacement systems that address the continuum of care for end-stage ankle arthritis patients. We believe INFINITY's lower profile design and straightforward surgical approach expands our access to less complicated primary cases and will be an important catalyst in the ongoing market conversion from fusion procedures to total ankle replacement." The full analyst notes on Wright Medical Group are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/WMGI/report.pdf

--
Anika Therapeutics Inc. Analyst Notes
On June 16, 2014, Anika Therapeutics Inc.'s (Anika Therapeutics) stock increased by 2.07%, ending at $45.80. For the past three day trading period, the Company's stock slipped by 4.06% compared to the Nasdaq Composite which went down by 0.25% during the same trading period. The full analyst notes on Anika Therapeutics are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/ANIK/report.pdf

--
Accuray Incorporated Analyst Notes
On June 16, 2014, Accuray Incorporated's (Accuray) stock went up by 2.19%, closing at $9.32. Over the past six month trading period, Accuray's stock reflected an increase of 15.92% compared to the Nasdaq Composite which went up by 7.39% during the same six month trading session. The full analyst notes on Accuray are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/ARAY/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review